The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

There are worries about delayed complications, but many places won’t get paid if AF patients don’t spend the night in ...